JPMorgan Chase & Co. Issues Pessimistic Forecast for Molecular Partners (NASDAQ:MOLN) Stock Price

Molecular Partners (NASDAQ:MOLN) had its price objective lowered by stock analysts at JPMorgan Chase & Co. from $4.00 to $3.75 in a research note issued on Monday,Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target would indicate a potential downside of 12.46% from the stock’s current price.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Molecular Partners in a report on Monday, December 1st. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $7.88.

Molecular Partners Price Performance

NASDAQ MOLN opened at $4.28 on Monday. The company has a fifty day moving average price of $3.99 and a 200-day moving average price of $3.82. The firm has a market cap of $172.99 million, a price-to-earnings ratio of -2.23 and a beta of 1.08. Molecular Partners has a 1 year low of $3.36 and a 1 year high of $5.95.

Molecular Partners (NASDAQ:MOLN) last released its quarterly earnings results on Thursday, October 30th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.05. On average, research analysts anticipate that Molecular Partners will post -1.93 EPS for the current fiscal year.

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.